Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats

Journal of Pharmaceutical Sciences

Volumn 91, Issue 2, 2002, Pages 508-516

  Stepensky, David ^a   Golomb, Gershon ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Alendronate; Bisphosphonates; Mode of administration dependency; Pharmacodynamics; Pharmocokinetics

Indexed keywords

ALENDRONIC ACID; COLECALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; BONE CANCER; BONE DISEASE; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER CELL CULTURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DISPOSITION; DRUG INTERMITTENT THERAPY; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; MALE; NONHUMAN; OSTEOLYSIS; PARATHYROIDECTOMY; PHARMACODYNAMICS; PHARMACOKINETICS; RAT; THYROIDECTOMY; WALKER CARCINOMA;

EID: 0036169824     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10032     Document Type: Article

References (29)

1. Bisphosphonates in clinical medicine
2. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone disease
3. Bisphosphonates: A review of their pharmacokinetic properties
4. Role of pharmacokinetics and metabolism in drug discovery and development
5. Use of bisphosphonates in cancer patients
6. Bisphosphonates: From the laboratory to the clinic and back again
7. Rationale for the use of alendronate in osteoporosis
8. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
9. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
10. Fast (4-h) or slow (24-h) infusions of pamidronate disodium [aminohydroxypropylidene diphosphonate (APD)] as single shot treatment of hypercalcaemia
11. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy
12. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women
13. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss
14. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass
15. Disposition of alendronate following local delivery in a rat jaw
16. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: A promising perspective in the treatment of bone-related malignancies?
17. Development of a new in vitro model for studying implantable polyurethane calcification
18. The evaluation of bisphosphonates as potential drugs for calcium- related disorders
19. Nature of calcemic effect of 1,25-dihydroxyvitamin D3 in experimental hypoparathyroidism
20. Inhibition by diphosphonates of bone resorption induced by the Walker tumor in rat
21. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat
22. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
23. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats
24. Mechanisms of action of bisphosphonates: Information from animal models
25. Pharmacodynamic aspects of sustained release preparations
26. A peptide prodrug approach for improving bisphosphonate oral absorption
27. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination
28. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones